Vitamin D, B12, and Folate: The Most Over-Ordered and Over-Treated Labs in Primary Care

 

Vitamin D, B12, and Folate: The Most Over-Ordered and Over-Treated Labs in Primary Care

When low B12 is real vs. artifactual, the vitamin D debate that won't die, and why folate deficiency is now almost nonexistent.

These three labs are ordered reflexively on nearly every patient with fatigue, brain fog, or "just to check." And in most cases, the results either don't change management or lead to treatment of a "deficiency" that wasn't real. Let's bring some evidence-based clarity to the most over-ordered panel in primary care.

Vitamin B12

When to Test

Test B12 when there's a clinical reason: macrocytic anemia (MCV >100), peripheral neuropathy, cognitive changes, glossitis, or risk factors for deficiency (strict vegans, pernicious anemia, gastric bypass, metformin use, elderly with poor nutrition, chronic PPI use, Crohn's/celiac affecting the terminal ileum).

The Serum B12 Problem

Serum B12 is a notoriously unreliable test:

• A "low" B12 (200–400 pg/mL) does NOT always mean functional deficiency. Up to 30% of patients with low-normal B12 have no metabolic evidence of deficiency.
• Conversely, some patients with normal serum B12 have functional deficiency at the tissue level.
• Anti-intrinsic factor antibodies can interfere with some B12 assays, causing falsely normal results in pernicious anemia patients who are actually deficient.
• Pregnancy, oral contraceptives, and folate deficiency can all lower serum B12 without true deficiency.

The Confirmatory Test: Methylmalonic Acid (MMA)

MMA is the definitive test for B12 deficiency. B12 is a cofactor for the enzyme that converts methylmalonyl-CoA to succinyl-CoA. When B12 is deficient, MMA accumulates. An elevated MMA confirms functional B12 deficiency regardless of the serum B12 level. Homocysteine is also elevated in B12 deficiency but is less specific (it's also elevated in folate deficiency, hypothyroidism, renal failure, and aging).

The Decision Rule

B12 <200 pg/mL: True deficiency likely. Treat. Check MMA if diagnosis uncertain.
B12 200–400: Gray zone. Check MMA. If MMA elevated, treat. If MMA normal, deficiency is unlikely.
B12 >400: Deficiency excluded in most cases. Don't treat.
Exception: If clinical suspicion is high (neuropathy, macrocytic anemia) regardless of B12 level, check MMA.

Pernicious Anemia Workup

If B12 deficiency is confirmed, determine the cause. Pernicious anemia (autoimmune destruction of parietal cells) is the most important diagnosis to make because it requires lifelong parenteral or high-dose oral B12. Test: anti-intrinsic factor antibodies (highly specific, ~50% sensitive) and anti-parietal cell antibodies (more sensitive but less specific). Pernicious anemia is associated with other autoimmune conditions (autoimmune thyroiditis, vitiligo, type 1 diabetes) and carries an increased risk of gastric carcinoid tumors.

Don't Miss This

B12 deficiency can cause irreversible neurologic damage (subacute combined degeneration of the spinal cord) even without anemia. The neuropathy can precede hematologic changes. If a patient has unexplained neuropathy or gait problems, check B12 and MMA even if the CBC is normal.

Folate

The Short Version: You Almost Never Need to Check It

Since mandatory folic acid fortification of grain products in the US (1998), clinically significant folate deficiency has become rare in the general population. Serum folate is a poor test (it reflects recent dietary intake, not stores) and changes within days of eating folate-rich foods.

When Folate Testing Is Still Relevant

• Macrocytic anemia with normal B12 and normal MMA: Folate deficiency is in the differential (MMA is normal in folate deficiency, which distinguishes it from B12 deficiency; homocysteine is elevated in both).
• Alcohol use disorder: Alcoholism impairs folate absorption and is the most common cause of folate deficiency in developed countries.
• Malabsorption syndromes: Celiac disease, tropical sprue, short bowel syndrome.
• Medications: Methotrexate (folate antagonist), phenytoin, trimethoprim, sulfasalazine.
• Pregnancy: Folate is critical for neural tube closure. However, we supplement with folic acid rather than testing levels.

Clinical Pearl

RBC folate is a better reflection of tissue stores than serum folate (which is too labile). But even RBC folate is now rarely indicated outside of the specific scenarios above. For most primary care patients with fatigue, checking a folate level is not clinically useful.

Danger: Folate Can Mask B12 Deficiency

Giving folate to a patient who actually has B12 deficiency will correct the macrocytic anemia (because folate and B12 share a metabolic pathway for DNA synthesis) but will NOT prevent the neurologic damage of B12 deficiency. Always rule out B12 deficiency before treating macrocytic anemia with folate alone. This is why B12 should be checked first and MMA used to confirm.

Vitamin D

The Ongoing Debate

Vitamin D testing and supplementation is one of the most debated topics in medicine. The evidence has shifted significantly in recent years:

• The USPSTF (2021) found insufficient evidence to recommend screening for vitamin D deficiency in asymptomatic adults.
• The VITAL trial and other large RCTs showed that vitamin D supplementation in unselected adults does not reduce fracture risk, cardiovascular events, or cancer incidence.
• The Endocrine Society (2024) updated guidelines recommending empiric supplementation (1000–2000 IU/day) for certain high-risk groups without routine testing.

The Thresholds

• <12 ng/mL (30 nmol/L): True deficiency. Risk of osteomalacia (adults), rickets (children). Treat.
• 12–20 ng/mL: Insufficiency per some guidelines. Clinical significance debated.
• 20–30 ng/mL: The "gray zone" that generates the most overtesting and overtreatment. The IOM considers 20 ng/mL sufficient for bone health in most people.
• >30 ng/mL: Sufficient by virtually all criteria.
• >50 ng/mL: No proven additional benefit. Risk of toxicity begins above 100 ng/mL.

When to Test Vitamin D

Test When You See

• Osteoporosis or osteomalacia
• Recurrent fractures or unexplained bone pain
• Chronic kidney disease (impaired 1-alpha hydroxylation)
• Malabsorption syndromes (celiac, IBD, short bowel, gastric bypass)
• Medications affecting vitamin D metabolism (anticonvulsants, glucocorticoids, antiretrovirals)
• Hyperparathyroidism workup
• Unexplained hypocalcemia
• Elderly in institutional settings with limited sun exposure

Do NOT Routinely Test

• Asymptomatic adults without risk factors
• "Just to check" as part of a wellness panel
• Patients with fatigue (vitamin D deficiency is very rarely the cause of nonspecific fatigue)

The Pitfalls

• Overtesting asymptomatic patients: Universal vitamin D screening is not recommended and generates a cascade of unnecessary supplementation, retesting, and follow-up.
• Treating "insufficiency" (20–30 ng/mL) aggressively: The evidence for treating levels in this range is weak for most outcomes. Modest supplementation (1000–2000 IU/day) is reasonable for at-risk groups, but high-dose loading protocols for levels of 25 are not evidence-based.
• Checking 1,25-dihydroxyvitamin D instead of 25-hydroxyvitamin D: The correct test for assessing vitamin D status is 25(OH)D. The 1,25(OH)2D test measures the active hormonal form, which is tightly regulated and does NOT reflect stores. It's only indicated in specific scenarios (granulomatous disease, CKD, suspected vitamin D-dependent rickets).
• Vitamin D toxicity from oversupplementation: While rare, it's being seen more often with unregulated high-dose supplementation. Hypercalcemia, nephrocalcinosis, and renal failure can result. Monitor levels if the patient is taking >4000 IU/day.

Quick Reference: When to Test What

Lab	Test When	Don't Test When	Confirm With
B12	Macrocytic anemia, neuropathy, risk factors for deficiency, metformin use	Nonspecific fatigue, "wellness" screening	MMA (elevated = true deficiency)
Folate	Macrocytic anemia with normal B12/MMA, alcoholism, malabsorption, methotrexate use	Routine screening (fortification has made deficiency rare)	RBC folate (better than serum); homocysteine (elevated in both B12 and folate deficiency)
Vitamin D (25-OH)	Osteoporosis, CKD, malabsorption, unexplained bone pain, hyperparathyroidism workup	Asymptomatic adults without risk factors, "just to check," nonspecific fatigue	PTH if hyperparathyroidism suspected; calcium levels

Bottom Line

B12, folate, and vitamin D are important nutrients, but the lab tests for them are overordered, poorly interpreted, and frequently lead to unnecessary treatment. Serum B12 is unreliable in the gray zone—use MMA to confirm. Folate deficiency is now rare and almost never needs checking unless there's macrocytic anemia or specific risk factors. And vitamin D screening in asymptomatic adults is not supported by current evidence—save the test for patients with real risk factors and treat the clinical condition, not the number.

Stay sharp out there.

Tumor Markers in Primary Care: When to Order, When to Step Away, and Why Screening Causes More Harm Than Good

 

Tumor Markers in Primary Care: When to Order, When to Step Away, and Why Screening Causes More Harm Than Good

PSA, CA-125, CEA, AFP—the tests that cause the most unnecessary panic in your practice.

Tumor markers are among the most misused tests in primary care. They get ordered for vague abdominal pain, pelvic discomfort, fatigue, or "just to be thorough"—and then a mildly elevated result triggers imaging, referrals, biopsies, and patient anxiety for a condition that doesn't exist. The core principle: tumor markers are for monitoring known cancers, not for screening asymptomatic patients (with limited exceptions).

The Markers: What They Do and Don't Tell You

Marker	Primary Cancer Association	Non-Cancer Causes of Elevation	Role in Primary Care
PSA	Prostate cancer	BPH, prostatitis, recent ejaculation, bike riding, UTI, age	Screening (shared decision-making for men 55–69); monitoring after treatment
CA-125	Ovarian cancer	Endometriosis, fibroids, PID, pregnancy, menstruation, cirrhosis, CHF, peritonitis, any peritoneal/pleural inflammation	Monitoring known ovarian cancer. NOT for screening pelvic pain.
CEA	Colorectal cancer	Smoking (most common), IBD, pancreatitis, cirrhosis, peptic ulcer, hypothyroidism	Monitoring colorectal cancer post-treatment. NOT for screening.
AFP	Hepatocellular carcinoma, germ cell tumors	Pregnancy, hepatitis, cirrhosis (regenerating nodules)	HCC surveillance in cirrhosis patients (with ultrasound every 6 months). Germ cell tumor monitoring.
CA 19-9	Pancreatic cancer	Biliary obstruction, cholangitis, pancreatitis, cirrhosis. Not expressed in Lewis antigen-negative patients (~5–10%).	Monitoring known pancreatic cancer. NOT for screening abdominal pain.
HCG	Gestational trophoblastic disease, germ cell tumors	Pregnancy (obviously), marijuana use (rarely), pituitary HCG production in postmenopausal women	Monitoring trophoblastic disease and germ cell tumors post-treatment.

The Rules That Prevent Harm

1. CA-125 Is NOT a Screening Test for Ovarian Cancer

This is the most commonly violated rule. CA-125 is elevated in roughly 80% of advanced ovarian cancer but only 50% of early-stage disease. Meanwhile, it's elevated in dozens of benign conditions: endometriosis, fibroids, PID, menstruation, pregnancy, and any cause of peritoneal or pleural inflammation. The USPSTF recommends against screening for ovarian cancer (including CA-125 and transvaginal ultrasound) in average-risk women because screening does not reduce mortality and leads to unnecessary surgeries, some with serious complications.

The Harm

Ordering CA-125 for "pelvic pain" in a premenopausal woman will frequently return a mildly elevated result from endometriosis, a corpus luteum cyst, or menstruation—triggering imaging, surgical consultation, and sometimes unnecessary oophorectomy. Do not order CA-125 as a screening test in average-risk women. It is appropriate for monitoring response in known ovarian cancer or evaluating a suspicious adnexal mass in a postmenopausal woman in conjunction with imaging.

2. PSA: Shared Decision-Making, Not Reflexive Ordering

Per USPSTF (2018, reaffirmed): for men 55–69, PSA screening should be an individual decision made after shared decision-making about benefits and harms. Not recommended for men ≥70 or men with <10-year life expectancy. Key points:

• PSA >4 ng/mL is traditionally considered the threshold, but many cancers occur below 4 and many benign conditions elevate PSA above 4.
• PSA velocity (rate of change) and PSA density (PSA relative to prostate volume) improve specificity.
• For screening, discuss overdiagnosis and overtreatment. Many screen-detected prostate cancers are low-grade and would never cause symptoms or death.

3. CEA Doesn't Screen for Colorectal Cancer

CEA is only useful for monitoring known CRC post-resection (rising levels may indicate recurrence). Smokers commonly have elevated CEA without cancer. It should never be ordered as a CRC screening test—colonoscopy and stool-based tests (FIT, Cologuard) are the appropriate screens.

4. AFP Has a Defined Surveillance Role

AFP plus abdominal ultrasound every 6 months is the recommended HCC surveillance strategy in patients with cirrhosis (any etiology) and chronic hepatitis B without cirrhosis who meet risk criteria. Outside of this specific surveillance context, AFP should not be ordered for vague abdominal symptoms.

The Pitfalls

• Ordering tumor markers for nonspecific symptoms: This creates false-positive results, unnecessary imaging, invasive follow-up procedures, and patient anxiety—without improving outcomes.
• Using tumor markers to diagnose cancer: Tumor markers support diagnosis in the right clinical context but are NEVER diagnostic on their own. Tissue biopsy is required.
• Not knowing the non-cancer causes: Every tumor marker has a long list of benign elevations. If you don't know the list, you'll over-investigate every positive.
• Ordering panels: "Tumor marker panels" that include CA-125, CEA, CA 19-9, AFP, and CA 15-3 together are almost never indicated in primary care. They generate a statistically inevitable false positive and do not improve cancer detection.
• Repeating tumor markers as "follow-up" without oncology guidance: Post-treatment tumor marker surveillance should be directed by the oncology team, not primary care guesswork.

Bottom Line

Tumor markers are monitoring tools, not screening tools (with the narrow exceptions of PSA with shared decision-making and AFP in cirrhosis surveillance). Ordering them for nonspecific symptoms is one of the most reliably harmful testing decisions in primary care. Know what each marker does, know its benign causes, and resist the urge to order a "cancer panel" for reassurance. The reassurance it provides is false, and the anxiety it generates is real.

Stay sharp out there.

HbA1c Pitfalls: When the Number Lies

 

HbA1c Pitfalls: When the Number Lies

Hemoglobinopathies, iron deficiency, CKD, and transfusions all break A1c. Here's when to trust it and when to use alternatives.

HbA1c is the cornerstone of diabetes diagnosis and monitoring. But it measures glycated hemoglobin, which means anything that alters hemoglobin or RBC lifespan will alter the A1c—independent of blood glucose. In your patients with sickle cell trait, iron deficiency, chronic kidney disease, or recent transfusions, the A1c may be telling you a completely different story than what their glucometer shows.

How A1c Works (and Why It Breaks)

A1c measures the percentage of hemoglobin A molecules with glucose attached. It reflects average blood glucose over the preceding 2–3 months (the lifespan of an RBC). This works perfectly when RBC lifespan and hemoglobin structure are normal. When they're not, the test becomes unreliable.

Conditions That Falsely LOWER A1c

These conditions shorten RBC lifespan or increase RBC turnover, giving glucose less time to glycate hemoglobin:

• Hemolytic anemias (autoimmune, G6PD deficiency, hereditary spherocytosis, sickle cell disease)
• Chronic kidney disease (especially on EPO therapy—accelerated erythropoiesis produces younger RBCs)
• Recent blood transfusion (dilutes the patient's glycated hemoglobin with donor RBCs)
• Acute or chronic blood loss (reticulocytosis = younger RBCs)
• Splenomegaly (increased RBC destruction)
• Pregnancy (hemodilution + increased RBC turnover, especially 2nd/3rd trimester)
• Hemoglobin variants: HbS (sickle), HbC, HbE can interfere with some assay methods (though newer methods handle this better)

Clinical Impact

A patient with sickle cell trait and a "normal" A1c of 5.8% may actually have diabetes. A patient on dialysis with an A1c of 6.0% may have average glucoses much higher than 126 mg/dL. If the A1c doesn't match the home glucose readings or clinical picture, suspect interference.

Conditions That Falsely RAISE A1c

These conditions extend RBC lifespan or otherwise increase glycation time:

• Iron deficiency anemia (the most common cause of falsely elevated A1c—iron-deficient RBCs live longer and accumulate more glycation)
• B12/folate deficiency (impaired erythropoiesis = older circulating RBCs)
• Splenectomy (RBCs not being cleared as quickly)
• Alcoholism (forms acetaldehyde-hemoglobin adducts that some assays measure as A1c)
• Chronic opioid use (reported association with falsely elevated A1c)
• Hypertriglyceridemia (can interfere with some assay methods)

The Iron Deficiency Trap

This one trips up NPs constantly. A patient with untreated iron deficiency anemia may have an A1c of 6.8%—technically "diabetic"—that drops to 5.5% after iron repletion. Always check for and correct iron deficiency before diagnosing diabetes based on A1c alone. This is especially important in menstruating women and patients with celiac disease or chronic GI blood loss.

When to Use Alternatives to A1c

Alternative Test	What It Measures	When to Use
Fructosamine	Glycated serum proteins (mainly albumin); reflects 2–3 week average glucose	Hemoglobinopathies, recent transfusion, dialysis, any condition making A1c unreliable. Not useful in hypoalbuminemia (nephrotic syndrome, cirrhosis).
Glycated albumin	Similar to fructosamine; 2–3 week average	Same indications as fructosamine; may be slightly more standardized
CGM (Continuous Glucose Monitoring) data	Real-time and ambulatory glucose profiles; calculates GMI (Glucose Management Indicator)	The gold standard when A1c is unreliable. Provides time in range, variability, and hypoglycemia data. Increasingly accessible.
Fasting glucose / OGTT	Point-in-time or 2-hour post-load glucose	For initial diabetes diagnosis when A1c is suspect; OGTT is the gold standard for gestational diabetes

Ethnic and Genetic Variation

A1c levels can vary by race and ethnicity independent of glucose levels. African American, Hispanic, and Asian patients tend to have A1c values 0.3–0.4% higher than White patients at the same average glucose. This is partially explained by differences in hemoglobin glycation rates and RBC survival. Current diagnostic thresholds (6.5% for diabetes) apply uniformly, but this variation may contribute to diagnostic disparities.

The Pitfalls Summary

• Diagnosing diabetes by A1c alone in a patient with iron deficiency: Correct the iron first, then recheck.
• Trusting A1c in sickle cell disease/trait: Use fructosamine or CGM data instead.
• Monitoring A1c in dialysis patients: A1c underestimates glucose control; use glycated albumin or CGM.
• Post-transfusion A1c: Wait at least 3 months after transfusion for a reliable A1c.
• A1c discordant with home glucose logs: Always investigate—interference from one of the conditions above, or inaccurate glucometer readings, or selective testing by the patient.
• Using A1c for gestational diabetes diagnosis: A1c is NOT recommended for GDM screening. OGTT is the standard.

Bottom Line

A1c is a powerful tool when hemoglobin and RBC lifespan are normal. In patients with hemoglobinopathies, iron deficiency, CKD, hemolysis, or recent transfusion, it lies—sometimes enough to misdiagnose or under-treat diabetes. Know the conditions that raise it falsely (iron deficiency is #1), know the conditions that lower it falsely (hemolysis and CKD), and use fructosamine or CGM when A1c can't be trusted.

Stay sharp out there.

STI Testing Beyond Syphilis: HIV Algorithms, GC/CT NAAT, and the Herpes Serology Dilemma

 

STI Testing Beyond Syphilis: HIV Algorithms, GC/CT NAAT, and the Herpes Serology Dilemma

The testing rules that have changed, the test you probably shouldn't be ordering, and the window periods that still trip everyone up.

The syphilis post covered one STI in depth. But the full STI panel has its own set of testing nuances, window periods, and pitfalls that new NPs need to master. HIV testing has evolved dramatically with 4th-generation assays, gonorrhea/chlamydia NAAT is site-specific, and herpes serology is the test that causes more unnecessary distress than almost any lab in primary care.

HIV Testing: The Modern Algorithm

4th-Generation Ag/Ab Combo Test (The Standard)

The current recommended initial screen is the 4th-generation HIV-1/2 antigen/antibody combination immunoassay. It detects both HIV antibodies AND p24 antigen, shortening the window period to approximately 2–4 weeks after exposure (compared to 3–12 weeks for older antibody-only tests).

The CDC Recommended Algorithm

1. 4th-gen Ag/Ab combo test (screen). If nonreactive → negative. Done.
2. If reactive → HIV-1/HIV-2 antibody differentiation immunoassay (confirmatory).
3. If differentiation assay is indeterminate or negative → HIV-1 RNA (NAT) to detect acute infection (p24 antigen-positive but antibody-negative = acute HIV).

Key Pitfalls

• Western blot is obsolete for HIV confirmation. The differentiation immunoassay has replaced it. If your lab is still using Western blot, they're outdated.
• The window period still exists: 4th-gen tests can miss very early acute infection (<2 weeks). If exposure was very recent and clinical suspicion is high (acute retroviral syndrome), order an HIV-1 RNA (viral load) directly.
• PrEP patients: HIV testing every 3 months per guidelines. Always use the 4th-gen combo, not a rapid antibody-only test, which has a longer window period.
• Universal screening: CDC recommends all adults 13–64 be tested at least once, regardless of risk factors. All pregnant patients should be tested at the first prenatal visit.

Gonorrhea and Chlamydia: NAAT Is King

Nucleic Acid Amplification Testing (NAAT)

NAAT is the gold standard for GC/CT detection—far more sensitive than culture. Key points:

• Site-specific testing: Urogenital NAAT does NOT detect pharyngeal or rectal infections. If the patient has risk factors for extragenital exposure, you must specifically order pharyngeal and rectal NAATs. This is routinely missed.
• Specimen type: First-void urine (for urethral/cervical) or swab (vaginal self-swab is FDA-approved and equally accurate). Urine testing in women is less sensitive than vaginal swab.
• Test of cure (TOC): For GC, repeat NAAT at 14 days post-treatment (not sooner—dead organisms can cause false-positive NAAT up to 14 days). For CT, TOC is recommended for pregnant patients and when adherence is uncertain; retest at 4 weeks.
• Reinfection screen: Retest ALL patients treated for GC or CT at 3 months (high reinfection rates). This is the most commonly skipped follow-up in STI management.

Pitfall

A negative urine GC/CT in a patient with pharyngeal symptoms or rectal complaints means nothing—you tested the wrong site. Always ask about sexual practices to determine which sites need testing. MSM should routinely be screened at all three sites (urogenital, pharyngeal, rectal).

Herpes Serology: The Test You Probably Shouldn't Order

The CDC Does Not Recommend Routine HSV Screening

This is the most controversial testing decision in STI medicine. The CDC explicitly recommends against routine serologic screening for HSV in asymptomatic individuals. Here's why:

• HSV-1 seroprevalence is ~50–70% in the US adult population. A positive HSV-1 IgG tells you almost nothing clinically useful—it could be oral herpes from childhood, genital HSV-1, or completely asymptomatic carriage.
• HSV-2 IgG has a significant false-positive rate at low index values (1.1–3.5). The test has poor positive predictive value in low-prevalence populations, causing unnecessary psychological harm, relationship disruption, and anxiety.
• A positive HSV IgG doesn't tell you the site of infection, when it was acquired, or whether the patient is or will be symptomatic.

When Herpes Testing IS Appropriate

• Active genital lesions: PCR swab of the lesion (not serology) is the test of choice. PCR is far more sensitive than viral culture.
• Recurrent genital symptoms suspicious for herpes but prior swab negative: Type-specific HSV IgG (HSV-1 and HSV-2 separately) can help confirm diagnosis.
• Partner of someone with known genital herpes: Type-specific serology can determine if the uninfected partner already has antibodies.
• HIV-positive patients: Serologic screening for HSV-2 is reasonable given increased risks.
• Pregnancy with unknown HSV status and partner with known genital herpes: Serology helps guide suppressive therapy decisions near delivery.

The Low-Index-Value Trap

An HSV-2 IgG index value of 1.1–3.5 has a high false-positive rate and should be confirmed with a supplemental assay (like the Biokit HSV-2 rapid test or the University of Washington Western blot, the gold standard). Do NOT diagnose a patient with genital herpes based on a low-positive HSV-2 IgG alone. The psychological and relational damage from a false diagnosis is real and lasting.

Trichomonas

NAAT is now the most sensitive test for Trichomonas vaginalis and is preferred over wet mount (which misses up to 50% of infections). Many GC/CT NAAT platforms now include trichomoniasis. Screen sexually active women with vaginal symptoms, and consider routine screening in high-prevalence populations (especially Black women, who have disproportionately high rates).

Screening Summary by Population

Population	What to Screen	How Often
All adults 13–64	HIV (4th-gen)	At least once
Sexually active women <25 (or ≥25 with risk factors)	GC/CT (urogenital NAAT)	Annually
MSM	HIV, syphilis, GC/CT (all 3 sites), HCV (if HIV+)	At least annually; every 3–6 months if high risk
Pregnant patients	HIV, syphilis (×3), HBV, GC/CT, HCV	First prenatal visit; repeat syphilis at 28 weeks and delivery
PrEP patients	HIV (4th-gen), syphilis, GC/CT (all sites), renal function	Every 3 months
Asymptomatic individuals	NOT: HSV serology, routine trichomoniasis	Do not screen routinely

Bottom Line

HIV testing has evolved—use the 4th-gen combo and stop relying on Western blot. GC/CT testing must be site-specific to be useful. Herpes serology should almost never be ordered routinely and causes more harm than good in asymptomatic patients. And the most commonly missed step in all of STI management: the 3-month retest after treating GC or CT.

Stay sharp out there.

Coagulation Studies: PT/INR, aPTT, D-dimer, and Fibrinogen Demystified

 

Coagulation Studies: PT/INR, aPTT, D-dimer, and Fibrinogen Demystified

When a prolonged aPTT is lupus anticoagulant vs. factor deficiency vs. heparin contamination—and why D-dimer is the most overordered test in the ED.

Coagulation studies get ordered constantly but are interpreted correctly far less often. The most common mistakes: ordering a D-dimer on a patient who clearly needs imaging, panicking about a mildly prolonged aPTT in a preop patient, and missing the lupus anticoagulant connection that ties directly into this series. Let's decode the panel.

The Tests and What They Measure

Test	Pathway	What It Assesses	Prolonged By
PT (Prothrombin Time) / INR	Extrinsic + common pathway (Factors VII, X, V, II, fibrinogen)	Warfarin monitoring; liver synthetic function	Warfarin, liver disease, vitamin K deficiency, DIC, factor VII deficiency
aPTT (Activated Partial Thromboplastin Time)	Intrinsic + common pathway (Factors XII, XI, IX, VIII, X, V, II, fibrinogen)	Heparin monitoring; intrinsic factor deficiencies; lupus anticoagulant screen	Heparin, factor deficiencies (hemophilia A/B), lupus anticoagulant, von Willebrand disease, DIC
D-dimer	Fibrinolysis	Detects fibrin degradation products	VTE, PE, DIC, surgery, trauma, pregnancy, malignancy, infection, inflammation, age
Fibrinogen	Common pathway	Clotting substrate; acute-phase reactant	Low in DIC, severe liver disease, massive hemorrhage. High in inflammation, pregnancy.

The Interpretation Patterns

PT/INR	aPTT	Think About
Prolonged	Normal	Warfarin therapy, early vitamin K deficiency, early liver disease, isolated factor VII deficiency
Normal	Prolonged	Heparin therapy, lupus anticoagulant, hemophilia A (factor VIII) or B (factor IX), von Willebrand disease, factor XI/XII deficiency, specimen contamination with heparin
Prolonged	Prolonged	DIC, severe liver disease, common pathway factor deficiency (X, V, II, fibrinogen), supratherapeutic anticoagulation, massive transfusion
Normal	Normal	Normal coagulation; does NOT exclude platelet disorders or von Willebrand disease (mild forms may have normal aPTT)

The Mixing Study: The Tiebreaker

When the aPTT is prolonged and the cause is unclear, a mixing study is the next step. The patient's plasma is mixed 1:1 with normal pooled plasma:

• aPTT corrects (normalizes with mixing): Factor deficiency—the normal plasma provides the missing factor. Investigate for hemophilia, vWD, or other factor deficiencies.
• aPTT does NOT correct: An inhibitor is present, blocking the coagulation pathway. The two most common inhibitors: lupus anticoagulant (the most common) and acquired factor VIII inhibitor (rare but serious).

The Lupus Anticoagulant Connection

This ties directly to the antiphospholipid antibody post in this series. Lupus anticoagulant (LA) paradoxically prolongs the aPTT in vitro but causes clotting in vivo. A prolonged aPTT that doesn't correct on mixing study + clinical thrombosis = suspect APS. Key points: LA interferes with phospholipid-dependent coagulation assays (hence the prolonged aPTT), but it's a pro-thrombotic condition. Never give a patient with suspected APS FFP or factor replacement for a "prolonged aPTT"—the prolongation is the antibody, not a bleeding diathesis.

D-dimer: The Most Overordered Test in Emergency Medicine

When D-dimer Is Useful

D-dimer has high sensitivity but low specificity for VTE. Its clinical value is as a rule-out test in low-to-moderate pretest probability patients:

• Low/moderate Wells score for PE or DVT + negative D-dimer = VTE excluded. No imaging needed.
• Age-adjusted D-dimer cutoffs (age × 10 for patients >50) improve specificity without sacrificing sensitivity.

When D-dimer Is Useless (or Harmful)

• High pretest probability: If the Wells score indicates PE/DVT is likely, skip the D-dimer and go straight to imaging (CT-PA or duplex ultrasound). A negative D-dimer in high-probability patients does NOT reliably exclude VTE.
• Hospitalized patients: D-dimer is elevated in almost every hospitalized patient (surgery, infection, inflammation, immobilization). It has almost zero specificity in this population.
• Pregnancy: D-dimer rises physiologically throughout pregnancy. Standard cutoffs don't apply. Imaging is generally preferred for suspected VTE in pregnancy.
• Active cancer, recent surgery, trauma, elderly patients: D-dimer is chronically elevated. A positive result tells you nothing useful.

The Harm of Overordering

Ordering D-dimer on a high-probability patient creates a dilemma: if it's negative (which it sometimes is even with PE), you might falsely reassure yourself. If it's positive (which it almost always is in sick patients), you've ordered a useless test that now mandates imaging anyway. Use clinical decision rules (Wells, PERC) first. D-dimer is for low/intermediate probability only.

D-dimer in DIC

In the context of sepsis or obstetric emergencies, a markedly elevated D-dimer with concurrent thrombocytopenia, prolonged PT/aPTT, and low fibrinogen = DIC. Here, D-dimer has a different role: it's part of the DIC score, not a VTE screen.

Fibrinogen: The Overlooked Marker

• Low fibrinogen (<200): DIC (consumed), severe liver disease (not synthesized), massive hemorrhage (diluted), rare congenital hypofibrinogenemia
• Very low fibrinogen (<100): Critical—risk of uncontrollable bleeding. Replace with cryoprecipitate.
• High fibrinogen: Acute-phase reactant. Elevated in infection, inflammation, pregnancy, malignancy. Also an independent cardiovascular risk factor.

DIC: The Pattern to Recognize

DIC is not a single lab result—it's a pattern across multiple tests in the right clinical context (sepsis, trauma, obstetric emergency, malignancy):

• Prolonged PT and aPTT
• Thrombocytopenia (platelets being consumed)
• Elevated D-dimer (fibrinolysis)
• Low fibrinogen (consumed)
• Schistocytes on peripheral blood smear (microangiopathic hemolysis)

Pediatric Note

Neonates have physiologically prolonged PT and aPTT due to immature clotting factor production (especially vitamin K-dependent factors). This normalizes by 6 months. Always use age-appropriate reference ranges for neonatal and pediatric coagulation studies. Vitamin K deficiency bleeding (formerly "hemorrhagic disease of the newborn") is prevented by routine vitamin K injection at birth—a critical reason to never skip it.

Preoperative Coagulation Testing: When It's Needed (and When It Isn't)

Routine preoperative PT/aPTT in patients with no personal or family history of bleeding and no clinical evidence of a bleeding disorder is not recommended per multiple Choosing Wisely guidelines. A thorough bleeding history is more informative than reflexive lab testing.

Order preoperative coagulation studies when: known bleeding disorder, anticoagulant use, liver disease, malnutrition, suspected malabsorption, or a positive bleeding history (easy bruising, heavy menses, prolonged bleeding after dental procedures or surgeries, family history of hemophilia or vWD).

The Pitfalls

• Heparin contamination: The most common cause of a falsely prolonged aPTT in hospitalized patients is a specimen drawn from a heparinized line. Always draw from a non-heparinized site or waste adequately before collecting.
• Assuming prolonged aPTT = bleeding risk: Lupus anticoagulant prolongs aPTT but causes thrombosis, not bleeding. Factor XII deficiency prolongs aPTT but has NO bleeding risk. The aPTT is not a bleeding predictor—it's a pathway assay.
• Using D-dimer as a screening test: D-dimer should only be ordered after calculating pretest probability. It is NOT a screening test for VTE.
• Forgetting that PT/INR reflects liver function: In a patient with no anticoagulant use, an elevated INR = impaired hepatic synthetic function until proven otherwise.
• Not checking fibrinogen in suspected DIC: Fibrinogen is often the forgotten component of the DIC workup. A falling fibrinogen is one of the most specific signs.
• Interpreting neonatal coag studies with adult norms: Neonates are physiologically "prolonged." Use neonatal reference ranges.

Bottom Line

PT measures the extrinsic pathway and liver synthetic function. aPTT measures the intrinsic pathway and is the test affected by heparin and lupus anticoagulant. D-dimer rules out VTE in low-probability patients and is useless in high-probability or hospitalized patients. Fibrinogen is the acute-phase reactant you're forgetting to check in DIC. And a prolonged aPTT that doesn't correct on mixing is lupus anticoagulant until proven otherwise—which means clotting, not bleeding.

Stay sharp out there.